Introduction Transforming care Investing in our people Accelerating possibilities Protecting the environment Creating value responsibly Appendix Creating value responsibly Governance Unit 2018 2019 2020 2021 2022 Number of executive directors # 1 1 1 1 1 1 Number of independent directors # 9 9 9 9 9 1 Number of women on Board of Directors # 3 3 3 3 3 1 Average tenure of independent board members (years) # 5 6 7 7 8 Number of non-executive/independent directors who sit on four or less public 1 company boards, including Boston Scientific # 9 9 8 9 9 Number of public company boards outside of Boston Scientific on which # 3 3 3 3 3 2 non-executive/independent directors can sit 3 Number of executive officers — women # 3 3 4 3 1 Performance period covered by Executive Compensation Plan Years 3 3 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Yes 4 Shares of common stock outstanding — each entitled to one vote No. of Votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,712 1,434,780,104 5 Total annual CEO compensation USD millions 13.97 15.76 13.77 16.06 16.94 Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.9 76.1 Lobbying USD millions 1.68 1.68 1.52 1.52 1.52 Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.22 0.18 Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21 0.11 1 Donna James will remain in her role as a director of the Company until her resignation becomes effective on the day of the 2023 Annual Meeting of Stockholders, which is scheduled to occur on May 4, 2023. 2 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board). For more information, please review our Corporate Governance Guidelines. 3 Executive officers: includes all executive officers listed in the Annual Report. 4 Total number of shares outstanding as listed on the cover page of the applicable Annual Report on Form 10-K. 5 Compensation is calculated in accordance with Item 402 of Reg S-K. 67 2022 Performance Report